Effect of dapagliflozin combined with metformin on visceral fat and serum chemokine-like receptor 1 levels in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease
Objective To investigate the effect of dapagliflozin combined with metformin on visceral fat and serum chemokine-like receptor 1(CMKLR1)levels in patients with type 2 diabetes mellitus(T2 DM)compli-cated with non-alcoholic fatty liver disease(NAFLD).Methods A total of 80 patients with T2DM and NAFLD who were diagnosed and treated in Cangzhou People's Hospital,Hebei Province from January 2020 to January 2023 were selected and divided into metformin group and dapagliflozin group by random number table method,with 40 cases in each group.The metformin group was treated with metformin hydrochloride sustained release tablets,and the dapagliflozin group was treated with dapagliflozin tablets on the basis of the metformin group.The clinical efficacy,glucose and lipid metabolism related indicators,inflammation related indicators,serum CMKLR1 level,body fat indicators,and adverse reactions were compared between the two groups.Results The total effective rate of dapagliflozin group was higher than that of metformin group[97.5％(39/40)vs 80.0％(32/40)](x2=4.507,P=0.034).After treatment,the levels of fasting blood glucose,glycosylated hemoglobin,total cholesterol,triglyceride,low-density lipoprotein cholesterol and homeostasis model assessment of insulin resistance index in the two groups were lower than those before treatment,and those in the dapagliflozin group were lower than those in the metformin group(all P＜0.05).The levels of interleukin-6,tumor necrosis factor-α and CMKLR1 in the two groups were lower than those before treatment,and those in the dapagliflozin group were lower than those in the metformin group(all P＜0.05).The visceral fat area,subcutaneous fat area,body weight and body mass index of the two groups were lower than those before treatment,and those of the dapagliflozin group were lower than those of the metformin group(all P＜0.05).During the treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Dapagliflozin combined with metformin in the treatment of T2DM with NAFLD can effectively reduce visceral fat and serum CMKLR1 level.
Type 2 diabetes mellitusDapagliflozinMetforminNon-alcoholic fatty liver diseaseChemokine-like receptor 1
万方数据
维普
